Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

OGEN

Oragenics Inc

May 06 • 04:00PM ET

0.6200

-0.0190 -2.97 %

Healthcare • Biotechnology • USA • Nano • AMEX

May 05, 8:35 AMOragenics enrolls first patients and activates second site in Phase IIa trial of lead candidate ONP-002 for concussion and mild traumatic brain injury

Peers: CTXR VNRX DSGN CTSO AIM PAVM OTLK AYTU HOTH AVGR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-9.26	Insider Own	0.47%	Shs Outstand	4.34M	Perf Week	2.60%
Market Cap	2.69M	Forward P/E	-	EPS next Y	-	Insider Trans	-1.02%	Shs Float	4.32M	Perf Month	9.35%
Enterprise Value	-5.48M	PEG	-	EPS next Q	-	Inst Own	4.99%	Short Float	16.28%	Perf Quarter	-17.49%
Income	-9.84M	P/S	-	EPS this Y	-	Inst Trans	3.20%	Short Ratio	2.78	Perf Half Y	-49.18%
Sales	0.00M	P/B	0.32	EPS next Y	-	ROA	-170.58%	Short Interest	0.70M	Perf YTD	-20.84%
Book/sh	1.94	P/C	0.32	EPS next 5Y	-	ROE	-243.94%	52W High	9.60 -93.54%	Perf Year	-88.47%
Cash/sh	1.94	P/FCF	-	EPS past 3/5Y	72.24% 64.78%	ROIC	-118.85%	52W Low	0.50 23.06%	Perf 3Y	-99.22%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.08% 7.76%	Perf 5Y	-99.95%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	83.36%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	5.64	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	45.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.64	EPS Q/Q	93.30%	SMA20	-3.72%	Beta	1.25	Target Price	2.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-11.99%	Rel Volume	0.11	Prev Close	0.64
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	-36.15%	Avg Volume	252.62K	Price	0.62
IPO	Oct 21, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	26,758	Change	-2.97%

May-05-26 08:30AM	Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. (GlobeNewswire)
Apr-20-26 09:00AM	Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury (GlobeNewswire)
Apr-13-26 08:30AM	Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury (GlobeNewswire) +12.95%
Mar-25-26 06:30PM	Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation (GlobeNewswire) -7.34%
Mar-17-26 08:30AM	ORAGENICS FILES ANNUAL REPORT ON FORM 10-K (GlobeNewswire)
08:30AM	Loading…
Mar-12-26 08:30AM	ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION (GlobeNewswire) +8.50%
Mar-11-26 08:30AM	ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION (GlobeNewswire) -9.90%
Mar-10-26 08:30AM	Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia (GlobeNewswire)
Feb-10-26 08:46AM	Oragenics previews targeted milestones for 2026 (TipRanks)
Feb-09-26 08:30AM	Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy (GlobeNewswire) -5.18%
Feb-04-26 08:40AM	Oragenics partners with Duck Flats Pharma to support FDA IND trial design (TipRanks)
Feb-03-26 08:30AM	Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program (GlobeNewswire) -7.23%
Feb-02-26 08:30AM	Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care (GlobeNewswire)
Jan-14-26 08:30AM	Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Nov-07-25 04:26PM	Oragenics: Q3 Earnings Snapshot (Associated Press Finance)
05:13AM	Loading…
Oct-08-25 05:13AM	Oragenics partners Receptor.AI for brain health candidate portfolio (Pharmaceutical Technology)
Aug-11-25 08:45AM	Oragenics Q2 2025 Shareholder Update (GlobeNewswire)
Aug-08-25 04:33PM	Oragenics: Q2 Earnings Snapshot (Associated Press Finance) -10.77%
Aug-01-25 06:55AM	Oragenics partners with Southern Star Research for Phase IIa trial of ONP-002 (Clinical Trials Arena)
Jul-31-25 08:30AM	Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial (GlobeNewswire)
Jul-16-25 08:39AM	Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development (GlobeNewswire) +5.97%
Jul-02-25 04:15PM	Oragenics Completes Approximately $16.5 Million Offering (GlobeNewswire) -7.10% +6.25%
Jul-01-25 08:31AM	Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants (GlobeNewswire) -59.42%
Jun-10-25 08:30AM	Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium (GlobeNewswire)
May-28-25 07:00AM	Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split (GlobeNewswire) -27.76%
May-13-25 08:30AM	Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia (GlobeNewswire) +8.89%
May-12-25 08:30AM	Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision (GlobeNewswire) +6.76%
May-09-25 04:38PM	Oragenics: Q1 Earnings Snapshot (Associated Press Finance) -6.33%
Apr-23-25 08:30AM	Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference (GlobeNewswire)
Apr-09-25 08:58AM	Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial (GlobeNewswire) +6.68%
04:30PM	Loading…
Apr-07-25 04:30PM	Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit (GlobeNewswire) -7.05%
Mar-27-25 08:30AM	Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress (GlobeNewswire)
Mar-18-25 05:33PM	Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K (GlobeNewswire)
Mar-06-25 09:30AM	Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) (GlobeNewswire)
Feb-25-25 08:30AM	Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment (GlobeNewswire)
Feb-24-25 08:30AM	Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health (GlobeNewswire)
Feb-11-25 08:30AM	Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment (GlobeNewswire) -6.78%
Feb-05-25 08:15AM	Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025 (GlobeNewswire)
Jan-21-25 08:15AM	Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO (GlobeNewswire)
Dec-16-24 08:09AM	Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference (GlobeNewswire) +5.91%
Oct-18-24 08:30AM	Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit (GlobeNewswire)
Oct-09-24 07:30AM	Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation (GlobeNewswire) +6.39%
Oct-08-24 08:45AM	Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 (GlobeNewswire) -9.21%
08:30AM	EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate (Benzinga)
Sep-05-24 04:30PM	Oragenics, Inc. Announces Closing of Public Offering (GlobeNewswire) -8.81%
Sep-04-24 08:36AM	Oragenics, Inc. Announces Pricing of Public Offering (GlobeNewswire) -46.20%
Aug-21-24 08:45AM	Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients (GlobeNewswire)
Aug-16-24 04:30PM	Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards (GlobeNewswire) -21.53% -9.73%
Aug-14-24 08:30AM	Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range (GlobeNewswire) -19.28%
Aug-12-24 08:30AM	Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study (GlobeNewswire) +48.57%
Aug-09-24 04:43PM	Oragenics: Q2 Earnings Snapshot (Associated Press Finance) +29.63%
09:00AM	As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032 (PR Newswire)
Aug-08-24 08:45AM	Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing (GlobeNewswire) +11.74%
08:30AM	EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase II Trials Underway (Benzinga)
Jul-10-24 08:00AM	Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients (GlobeNewswire) +11.32%
Jun-27-24 08:30AM	Oragenics Develops Automated Intranasal Device for Treating Concussed Patients (GlobeNewswire)
Jun-26-24 04:47PM	Oragenics, Inc. Announces Closing of Public Offering (GlobeNewswire)
Jun-25-24 08:30AM	Oragenics, Inc. Announces Pricing of Public Offering (GlobeNewswire) -23.37%
Jun-24-24 06:43PM	Oragenics, Inc. Announces Proposed Public Offering (GlobeNewswire) -9.37%
Jun-20-24 08:00AM	Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance (GlobeNewswire) -5.23%
May-22-24 08:00AM	Oragenics Appoints William Frank Peacock MD as Chief Clinical Officer (GlobeNewswire) -17.43%
May-17-24 08:00AM	Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine (GlobeNewswire) +42.07%
May-16-24 12:52PM	Oragenics to Start Phase 2 Concussion Treatment Drug Trial -- Shares Rise (MT Newswires)
08:00AM	Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial (GlobeNewswire)
May-15-24 01:07PM	Oragenics: Q1 Earnings Snapshot (Associated Press Finance)
May-07-24 08:00AM	Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia (GlobeNewswire) +24.07%
Apr-19-24 05:50PM	Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards (Business Wire) -6.19%
Apr-01-24 09:05AM	Oragenics, Inc. Files 10K and Provides Company Update (Business Wire)
Mar-18-24 07:00AM	Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion (Business Wire)
Mar-17-24 08:38AM	15 Highest Quality Probiotics For Gut Health (Insider Monkey)
Mar-05-24 07:45AM	Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion (Business Wire)
Mar-01-24 04:04PM	Oragenics Announces Closing of Public Offering (Business Wire)
Feb-27-24 09:25PM	Oragenics Announces Pricing of Public Offering (Business Wire) -22.47% -42.04%
04:33PM	Oragenics Announces Proposed Public Offering (Business Wire)
Feb-12-24 04:41PM	Oragenics, Inc. Announces Leadership Transition (Business Wire) -5.54% -11.47%
Feb-07-24 08:00AM	Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement (Business Wire) +24.08%
Feb-05-24 08:00AM	Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion (Business Wire) -6.06%
Jan-23-24 05:34PM	Oragenics Announces Termination of At-The-Market Offering Program (Business Wire)
Jan-02-24 07:30AM	Oragenics Completes Acquisition of Odyssey Healths Neurological Assets (Business Wire) +20.51%
Nov-10-23 09:19AM	Oragenics: Q3 Earnings Snapshot (Associated Press Finance)
Nov-02-23 07:00AM	Oragenics Issues Update to Shareholders (Business Wire)
Oct-18-23 08:30AM	Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors (Business Wire)
08:30AM	Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc. (ACCESSWIRE)
Oct-05-23 06:30AM	Oragenics to Acquire Odyssey Healths Neurological Drug Technology Pipeline Including Concussion Drug Candidate (Business Wire) +13.00%
Sep-29-23 04:00PM	Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets (Business Wire)
Aug-14-23 02:46PM	Oragenics: Q2 Earnings Snapshot (Associated Press Finance)
Aug-07-23 08:30AM	Oragenics, Inc. Announces Private Placement (Business Wire)
Jun-05-23 04:18PM	Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM (Business Wire)
May-12-23 06:32PM	Oragenics: Q1 Earnings Snapshot (AP Finance)
Mar-29-23 11:45AM	Oragenics to Participate in the World Vaccine Congress Washington (Business Wire)
Mar-14-23 08:30AM	Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE (Business Wire)
Mar-08-23 09:09AM	Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team (Business Wire)
Mar-01-23 01:47PM	Oragenics Looks To Boost Potency Of Its Nasal COVID-19 Vaccine With New Licensing Pact (Benzinga)
07:30AM	Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate (Business Wire)
Feb-03-23 07:30AM	Oragenics, Inc. Regains Compliance with NYSE American (Business Wire) +5.12%
Jan-30-23 02:24PM	7 Short-Squeeze Stocks to Buy Before They Soar (InvestorPlace) +7.58%
Dec-23-22 04:05PM	Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split (Business Wire) -6.69% -13.72%
Dec-22-22 07:30AM	Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate (Business Wire) +17.73%
Dec-20-22 04:36PM	Oragenics, Inc. Receives NYSE American Notice (Business Wire) -19.22%
Dec-19-22 04:34PM	Oragenics, Inc. Announces New Chair (Business Wire)

Oragenics, Inc. operates as a development-stage company, which engages in research and development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its technology and pipeline consist of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Lakewood Ranch, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Telling Fred	Director	Dec 12 '25	Sale	0.94	210	198	34,538	Dec 15 04:38 PM
Frederick W. Telling	Director	Dec 12 '25	Proposed Sale	0.91	210	192		Dec 12 06:28 PM
Odyssey Health, Inc.	10% Owner	Jun 18 '25	Sale	4.26	5,044	21,487	0	Jun 18 05:10 PM
Odyssey Health, Inc.	10% Owner	Jun 17 '25	Sale	4.46	2,000	8,920	5,044	Jun 18 05:10 PM
Odyssey Health, Inc.	10% Owner	Jun 16 '25	Sale	4.45	5,000	22,250	7,044	Jun 16 06:01 PM
Odyssey Health, Inc.	10% Owner	Jun 13 '25	Sale	4.27	5,000	21,350	12,044	Jun 16 06:01 PM
Odyssey Health, Inc.	Stockholder	Jun 10 '25	Proposed Sale	4.69	17,044	79,936		Jun 13 03:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OGEN

Oragenics Inc

Upgrade your Finviz experience